SingHealth Polyclinics, Singapore City, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.
Health Expect. 2021 Apr;24(2):431-443. doi: 10.1111/hex.13184. Epub 2021 Jan 12.
Gout treatment is not optimized globally, often due to therapeutic inertia by physicians or poor adherence to urate-lowering medications by patients. A patient decision aid (PDA) to facilitate shared decision making (SDM) in gout treatment may overcome these physician-patient barriers.
The study explored the views of physicians and patients on a novel locally designed gout treatment PDA prototype.
Qualitative descriptive design was used to gather data from in-depth-interviews (IDI) and focus group discussions (FGD). Data analysis was via thematic analysis. Emergent themes shaped a revised version of the PDA.
Adult Asian patients with recent acute gout exacerbations and local Primary Care Physicians (PCP) in Singapore were purposefully chosen. 15 patients with gout and 11 PCPs participated across three IDIs and six FGDs, with the investigators exploring their views of a prototype gout treatment PDA.
Patients and physicians generally concurred with the content and design of the PDA prototype. However, while patients preferred fewer treatment details, the PCPs desired more information. Patients preferred the display of statistics, while PCPs felt that numbers were not relevant to patients. The latter were hesitant to include treatment options that were unavailable in primary care. Both stakeholders indicated that they would use the PDA during a consultation. PCPs would need further training in SDM, given a lack of understanding of it.
Patients will be the prime users of the PDA. While their views differed partially from the physicians, both have jointly developed the novel gout treatment PDA.
全球范围内的痛风治疗并不理想,这通常是由于医生的治疗惰性或患者对降尿酸药物的依从性差。患者决策辅助工具(PDA)可促进痛风治疗中的共同决策(SDM),从而克服这些医患障碍。
本研究探讨了医生和患者对一种新型本地设计的痛风治疗 PDA 原型的看法。
使用定性描述性设计从深入访谈(IDI)和焦点小组讨论(FGD)中收集数据。数据分析采用主题分析。出现的主题塑造了 PDA 的修订版本。
新加坡的成年亚洲痛风急性发作患者和当地的初级保健医生(PCP)被有目的地选择。共有 15 名痛风患者和 11 名 PCP 参加了三次 IDI 和六次 FGD,研究人员探讨了他们对原型痛风治疗 PDA 的看法。
患者和医生普遍同意 PDA 原型的内容和设计。然而,虽然患者更喜欢较少的治疗细节,但 PCP 希望获得更多信息。患者更喜欢显示统计数据,而 PCP 认为数字与患者无关。后者对纳入初级保健中不可用的治疗方案犹豫不决。利益相关者均表示他们将在咨询期间使用 PDA。鉴于对 SDM 的理解不足,PCP 需要进一步接受 SDM 培训。
患者将是 PDA 的主要使用者。虽然他们的观点与医生部分不同,但两者共同开发了新型痛风治疗 PDA。